Loading people...
Michael Hyatt is an independent early-stage investor and technology entrepreneur currently operating within the broader global venture capital ecosystem. He previously served as a co-founder of Ginkgo Bioworks, a prominent synthetic biology enterprise that successfully transitioned to the public markets via a special purpose acquisition company in 2021, achieving an estimated peak market valuation exceeding $15 billion. Throughout his professional career, Hyatt has cultivated extensive strategic ties across the startup landscape, maintaining network associations with notable institutional players such as Sequoia Capital and Y Combinator. In his current investment capacity, he leverages his direct operational background to allocate capital and provide structural guidance to emerging founders navigating the complex initial phases of enterprise scaling. Today, Hyatt maintains a dedicated focus on funding early-stage biotechnology and enterprise software ventures while publicly sharing analytical insights regarding broader venture capital trends.
